Innovent’s $10.5 billion deal marks new model for China drugmakers
The Chinese biotech has added a major Pfizer collaboration to its growing roster of global deals, this time with a tighter commercial and profit-sharing partnership Key Takeaways: Co-commercialization deals…
Mega licensing deal lifts 3SBio profits but core sales slip
The Chinese drugmaker delivered sharply higher earnings, thanks to a bumper deal with Pfizer to develop a new cancer drug, but its older products came under pressure Key Takeaways: 3SBio’s…
RemeGen scores out-licensing triple play with AbbVie deal
The agreement marks the drug maker’s third such transaction since last year, setting records for both its largest upfront payment and highest total deal value Key Takeaways: PD-1/VEGF bispecific antibodies…
Lagging in the weight-loss market? Take Fosun’s GLP-1 pill
Playing catch-up in the anti-obesity business, Pfizer has bought global rights to an oral weight-loss drug from Fosun Pharma in another big licensing deal Key Takeaways: With the drug still…
3SBio gears up for drugs battle with $400 million equity move
After grabbing the spotlight this year with a big licensing deal, the Chinese drug developer is now raising extra funds for R&D and shedding a non-core subsidiary Key takeaways: 3SBio…
So big but so what? Innovent’s license deal fails to excite investors
The Chinese biotech is selling some cancer drug rights to a Japanese pharma giant for up to $11.4 billion, pocketing a big downpayment, so why did its stock price fall?…
INDUSTRY BRIEF: Trump eyes curbs on Chinese drugs, drawing industry pushback
The administration of U.S. President Donald Trump is weighing restrictions on the import of drugs and experimental therapies from China, a move that could disrupt the U.S. pharmaceutical industry and…
Recent Articles
RemeGen scores out-licensing triple play with AbbVie deal
9995.HK
688331.SHG
Lagging in the weight-loss market? Take Fosun’s GLP-1 pill
2196.HK
600196.SHG
